

**NEWS RELEASE**  
**TSX Venture Exchange: MEV**

## **Medical Ventures GAAME clinical update**

### *Updated physician feedback shows Gemini's continued influence on treatment*

**February 15, 2008 – Richmond, BC, Canada – MEDICAL VENTURES CORP.** (TSXV: MEV), a medical devices company specializing in products for the vascular and surgical markets, has released the following updated physician feedback from its recently-completed GAAME clinical trial.

The GAAME trial (for Gemini Angioplasty and Arterial Measurement Evaluation) was MEV's human clinical trial to assess the safety and effectiveness of the Metricath Gemini® dual-balloon catheter and to support the company's pre-market approval application for U.S. FDA approval of the device. Throughout the course of the study, the trial's principal investigators completed questionnaires administered for each patient about the device's performance. These results compile the investigators' responses relating to their use of the Metricath Gemini on 145 patients in 15 trial centres.

#### **Clinical utility results**

The compiled feedback again shows that the Metricath Gemini device influenced the doctors' course of treatment related to selecting stent size and post-dilating (further expanding) stents after implantation.

Specifically, the results indicate:

- Metricath was used to measure reference vessels and to pre-dilate (open up) lesions prior to stent implantation in 62% of cases (90/145). Direct stenting (implantation of a stent without pre-dilating the vessel in advance) occurred in 38% of cases (55/145).
- In 43% of pre-dilation cases (39/90), Metricath measurements influenced the target diameter for the treatment area.
- In 49% of pre-dilation cases (44/90), Metricath measurements influenced the physicians' stent size selection.
- Metricath measurements influenced the decision to post-dilate stents in 45% of direct stenting cases (25/55) and in 21% of pre-dilation cases (19/90).

"This final review of doctor feedback from the GAAME trial shows consistency with the preliminary reports issued in Q1 and Q4 of 2007," said Alexei Marko, president and chief operating officer. "Metricath showed utility as a measurement tool in nearly half of the pre-dilation cases, helping doctors to target ideal vessel diameter and to choose the best stent size to generate desired results. Further, we are pleased that the trial demonstrated the clinical utility of the Gemini's angioplasty function, with the dilatation balloon being used to effectively perform needed pre-dilatation of vessels and post-dilatation of under-expanded stents."

Medical Ventures submitted its pre-market approval application for the Metricath Gemini to the U.S. FDA on November 26, 2007. The company later submitted additional information as requested by the agency and is presently awaiting a response to its application.

- more -

*The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.*

### **Metricath featured at CRT 2008**

In a separate news item, the Metricath technology was featured this week at CRT 2008 (Cardiovascular Revascularization Therapies), a clinical symposium in Washington DC. Dr. Rajesh Dave, Chairman of Endovascular Medicine at the PinnacleHealth Heart & Vascular Institute (Harrisburg, PA) and course director of the C3 Global Cardiovascular Conference, discussed the Metricath System in a presentation entitled "Metricath: A Non-IVUS Tool to Measure Vessel Size and Vessel Expansion."

The session, which took place during an introduction of "Emerging Devices and Innovative Therapies," highlighted Metricath as a low-cost clinical measurement device and included a review of several peripheral revascularization cases where Metricath measurements directly influenced treatment sizing decisions.

### **About Medical Ventures Corp.**

Medical Ventures Corp. develops, manufactures and markets medical devices for the quickly growing vascular and surgical marketplace. MEV products help doctors treat a wide range of health concerns, including vascular disease and obesity. MEV products include the Metricath<sup>®</sup> arterial and in-stent measurement system and PeriPatch<sup>™</sup>, a line of surgical tissue and staple line reinforcement products. Medical Ventures is also a contract medical devices manufacturer. For more information, please visit: [www.medical-ventures.com](http://www.medical-ventures.com).

### **Investor contact**

Caren Holtby, Investor Relations Manager  
Medical Ventures Corp.  
604-805-8772 or [choltby@medical-ventures.com](mailto:choltby@medical-ventures.com)

### **Media contact**

Jessica Ruffen, Communications Manager  
Medical Ventures Corp.  
604-248-4136 or [jruffen@medical-ventures.com](mailto:jruffen@medical-ventures.com)

- 30 -

*Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.*